Biocon Biologics receives USFDA approval for Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for treating various ...

Cardiac problems associated with vascular endothelial growth factor inhibitors occur frequently in patients with cancer.

Biocon Biologics on Thursday said it has received an approval from the US health regulator to market a cancer treatment ...

FDA approves Biocon Biologics' Jobevne, a biosimilar Bevacizumab for cancer treatment, expanding access to affordable ...

The US sales of bevacizumab were around $2 billion in 2023. Amgen, Amneal, Celltrion and Pfizer are its competitors in the US ...

Existing treatments for endometriosis have changed little in the past 30 years and are often ineffective or have undesired ...

Several other angiogenesis mediators, such as the angiopoietin−TIE system, hypoxia inducible factor and integrin α V β 3, as well as naturally occurring inhibitors of angiogenesis, are also ...

An In-depth Market Research ReportThe Cancer Biologics Market is one of the fastest-growing segments within the global ...

Download this technical note to explore how a qualitative, real-time, high-throughput in vitro tube formation assay helps ...

Based on mouse data, DiVasta and Marc Laufer, HMS professor of obstetrics, gynecology, and reproductive biology at Boston ...

Tharimmune (THAR) announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to ...

Adcendo, a biotech company pioneering the development of first- and potential best-in-class antibody-drug conjugates (ADCs) ...